6 March 2026
ubispoke® - Commercial Experts in Heterocyclic Building Blocks
The complexity of rational drug design for small molecule therapeutics continues to evolve, offering a wide diversity of structural architectures and biological activities. Nitrogen-containing heterocycles (N-heterocycles) are a cornerstone of this evolution, featuring in approximately 82% of all FDA-approved small molecule drugs (Marshall et al., 2024). Their inclusion can significantly modulate key physicochemical properties - such as lipophilicity, solubility, hydrogen bonding, and dipole-dipole interactions - enhancing a drug candidate’s ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profile (Arnott and Planey, 2012).
The structural diversity enabled by nitrogen-containing heterocycles has contributed to an incredible array of approved therapeutics across oncology, anti-infectives, neurology, rare diseases, autoimmune, cardiovascular, endocrine, gastrointestinal, respiratory, mental health, and pain management areas.Analysis of FDA-approved small-molecule drugs from 2015–2024 shows a 23% increase in the proportion of drugs containing nitrogen heterocyclic motifs, compared with the previous decade (Vitaku, Smith and Njardarson, 2014). This growth reflects not only a higher prevalence of these motifs in drug structures but also a broader diversity of distinct heterocyclic scaffolds incorporated per molecule (Figure 1) Figure 1.
In particular, key heterocyclic structures such as pyridine, piperidine, pyrrolidine, piperazine, pyrimidine, indole, pyrazole, imidazole, morpholine, and benzimidazole have seen significant increases in occurrence over the past 10 years (Figure 2). (Ward and O’Boyle, 2025)
ubispoke® turns complex chemistry into commercial reality - delivering innovative, comprehensive, and agile manufacturing of advanced intermediates and key starting materials. With deep technical expertise, global supply chain reach, and proven specialism in highly-functionalised nitrogen heterocycles, we mitigate risk, accelerate development, and secure reliable supply. Our partnerships with pharmaceutical innovators and CDMOs deliver commercially advantageous solutions for the manufacture and scale-up of heterocyclic intermediates early in clinical candidate synthesis, supporting projects from Phase I through Phase III and into NDA submission for a seamless path from lab to market.
As an illustration, ubispoke® can supply key starting materials for the synthesis of Vimseltinib - an investigational CSF1R inhibitor (Figure 3) - while applying commerciality to science through route design and optimisation. Our credible expertise leverages deep process chemistry know-how to control yields, minimise impurities, and choose scalable, cost-efficient pathways over less effective alternatives.
Among these is the aminopyrimidonyl boronic acid (CAS 275890-48-8) – a compound that is difficult to access at commercial scale, as boronic acids are inherently unstable and prone to degradation under standard manufacturing conditions. ubispoke® have the capability to manufacture this product at volume, ensuring a robust, cost-effective, and secure supply chain (Figure 4).ubispoke® offers flexible manufacturing solutions, including GMP and non-GMP production, across a diverse portfolio of synthetic methodologies. With facilities in China, India, and Europe, we provide scalability from R&D gram-scale quantities to pilot (5-10 kg) and commercial-scale batches (50-500kg).
Global Supply Chain Excellence: Why India Matters
At ubispoke®, our ability to deliver commercially viable heterocyclic building blocks is underpinned by a robust and agile global supply chain. Among our strategic manufacturing locations, India plays a pivotal role in enabling cost-effective, scalable, and high-quality production of advanced intermediates.
Why India is a strategic hub for advanced intermediates
Proven manufacturing capability - India is home to the largest number of USFDA-approved pharmaceutical manufacturing facilities outside the United States. This regulatory maturity ensures that intermediates produced in India meet stringent global quality standards, supporting both GMP and non-GMP requirements across clinical and commercial phases.
Cost-Efficient Scale-Up - India offers a significant cost advantage in chemical manufacturing, often 30–40% lower than Western markets, without compromising on quality. This is especially critical for complex heterocyclic intermediates, where multi-step synthesis and purification demand both technical precision and economic feasibility.
Collaborative approach - Combined with our deep technical expertise helps our Indian partners bring decades of experience in heterocyclic chemistry, including the synthesis of nitrogen-rich scaffolds such as pyrimidines, indoles, and pyrazoles. This expertise enables ubispoke® to deliver tailored solutions for challenging intermediates like aminopyrimidonyl boronic acid (CAS 275890-48-8), which require advanced route design and impurity control.
Supply Chain Resilience - In response to global shift, such as the China+1 strategy and increasing regulatory scrutiny, India has emerged as a reliable alternative for sourcing critical pharmaceutical inputs. ubispoke® leverages this resilience to ensure uninterrupted supply of key starting materials, even in volatile market conditions.
Strategic Partnerships and Infrastructure - ubispoke® maintains flexible production capabilities across pilot and commercial scales (5–500 kg). This allows us to support rapid scale-up from early-phase development to full commercial launch, while maintaining control over timelines, costs, and quality.
ubispoke®: Bridging Innovation and Commercial Reality
By integrating India's manufacturing strengths into our global operations, we deliver a seamless path from molecule design to market-ready supply. Our ability to combine deep heterocyclic chemistry expertise with global supply chain agility makes us the ideal partner for pharmaceutical innovators seeking to accelerate development and reduce risk.
Whether you're sourcing a complex boronic acid, a functionalised pyrimidine, or a bespoke heterocyclic scaffold, ubispoke® ensures that your project benefits from technical excellence, commercial viability, and global reach.
Our expertise is rooted in over 50 years of experience in synthesising advanced intermediates for the pharmaceutical industry. We routinely supply tailored intermediates for marketed and late-stage small molecule drugs - functionalised with substituents such as fluoro, bromo, chloro, cyano, amino, carboxy, and trifluoromethyl groups. Examples Include those shown below.
At ubispoke®, our deep technical expertise, agile global manufacturing capabilities, and proven track record in heterocyclic synthesis make us the ideal partner for commercial-scale supply of critical nitrogen-containing building blocks. By partnering with ubispoke®, pharmaceutical innovators can reduce supply chain risk, accelerate timelines from clinical to commercial phases, and gain a strategic edge in the competitive small molecule drug development landscape.
Share your custom synthesis requirements, and our team will provide a statement of feasibility within five working days.
To discover how ubispoke® can support your commercial project, contact us at sales@ubichem.com or visit www.ubichem.com.
Structures referenced throughout Heterocyclic Building Blocks article.
References
Marshall, C.M., Federice, J.G., Bell, C.N., Cox, P.B. and Njardarson, J.T., 2024. An update on the nitrogen heterocycle compositions and properties of US FDA-approved pharmaceuticals (2013–2023). Journal of Medicinal Chemistry, 67(14), pp.11622-11655.
Vitaku, E., Smith, D.T. and Njardarson, J.T., 2014. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals: miniperspective. Journal of medicinal chemistry, 57(24), pp.10257-10274.
Ward, M. and O'Boyle, N., 2025. Analysis of the Structural Diversity of Heterocycles amongst European Medicines Agency Approved Pharmaceuticals (2014–2023). RSC Medicinal Chemistry.
Arnott, J.A. and Planey, S.L., 2012. The influence of lipophilicity in drug discovery and design. Expert opinion on drug discovery, 7(10), pp.863-875.